OREANDA-NEWS. The state registration of the first vaccine developed against COVID-19 in Russia must be postponed until the successful completion of the third stage of its clinical trials.

This is said in a letter sent to the head of the Ministry of Health, Mikhail Murashko, by the Association of Clinical Trials Organizations (ACTO).

The document signed by the Executive Director of ACTO, Svetlana Zavidova, notes that participation in tests of the drug Gam-Covid-Vac developed by the Gamaleya National Research Center for Epidemiology and Microbiology were passed by less than a hundred people, when during the third phase of trials, medicines are usually tested on several thousand people. At the same time, in the third stage information is collected not only about the effectiveness of the vaccine, but also about its safety for patients with weakened immunity, with various diseases, etc.

The drive to complete the development of a vaccine against COVID-19 as soon as possible is considered by ACTO to be a kind of relic, of the so-called heroic paradigm characteristic of the days of the pioneers of vaccination, while modern medical science adheres to standards that reduce risks to humans.